SAN DIEGO, CA — For patients facing relapsed or refractory large B-cell lymphoma (R/R LBCL), a new, combined analysis released by Kite (a Gilead Company) offers powerful and lasting hope.
At a major blood cancer meeting (ASH 2025), Kite presented updated findings on its personalized cell therapy, Yescarta$^circledR$. This treatment is being used in patients whose initial therapy failed, including those too sick for a standard stem cell transplant.
The most important takeaway:
The data shows that Yescarta offers a real chance at long-term survival. After two years, nearly 65% (64.9%) of patients treated with Yescarta were still alive. This is a huge leap compared to older treatments, which historically saw survival rates closer to 20% in this group.
What Else Matters to Patients?
-
Responses Last: A majority of patients who responded (61%) were still benefiting from the treatment one year later.
-
Safety is Predictable: The treatment’s safety profile was consistent and manageable across the different groups studied.
-
Feeling Better: Crucially, the analysis showed that after the initial recovery period (around three to five months), patients reported a significant and sustained improvement in their quality of life—allowing them to live better for the long term.
Kite emphasizes that these results reinforce their belief that Yescarta can be a curative option for aggressive forms of lymphoma.